(NASDAQ: GALT) Galectin Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.22%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 14.89%.
Galectin Therapeutics's earnings in 2025 is -$40,457,000.On average, 1 Wall Street analyst forecast GALT's earnings for 2025 to be -$31,389,528, with the lowest GALT earnings forecast at -$31,389,528, and the highest GALT earnings forecast at -$31,389,528. On average, 1 Wall Street analyst forecast GALT's earnings for 2026 to be -$28,186,515, with the lowest GALT earnings forecast at -$28,186,515, and the highest GALT earnings forecast at -$28,186,515.
In 2027, GALT is forecast to generate -$31,389,528 in earnings, with the lowest earnings forecast at -$31,389,528 and the highest earnings forecast at -$31,389,528.